Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic…
Activity of STAT3 degrader in preclinical model of cutaneous T-cell lymphoma (CTCL) validates selective STAT3 degradation as a potential therapeutic strategy for STAT3-driven T cell…